Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:




(I)

in which

each of A,B,D and E is independently C-$R^1$ ~~or N~~;

X is carbon;

Y is [[= C-$R^2$ ,]] N [[or C=O]];

Z is oxygen, sulphur, a $C_{1-6}$alkylene chain or a bond;

$R^1$ is independently selected from hydrogen, halogen, CN, nitro, $S(O)_xR^6$, $OR^6$, $SO_2NR^4R^5$, $CONR^4R^5$, $NR^4R^5$, $NR^7SO_2R^7$, $NR^7C(O)_xR^7$, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_{1-6}$alkyl, and aryl ~~or heteroaryl~~, the latter four ~~five~~ groups being optionally substituted by one or more substituents independently selected from 1-3 halogen atoms, -$OR^7$ and –$NR^4R^5$, $S(O)xR^8$, $C(O)NR^4R^5$, where x is 0,1 or 2;

~~$R^2$ is $C_{1-6}$alkyl which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, -$OR^9$ and –$NR^{10}R^{11}$;~~

$R^3$ is a quinoline ~~an aryl or heteroaryl~~ group, ~~each of~~ which is optionally substituted by one or more substituents independently selected from halogen, CN, nitro, $S(O)_xR^6$, $OR^7$, $SO_2NR^4R^5$, $CONR^4R^5$, $NR^4R^5$, $NR^7SO_2R^3$, $NR^7C(O)_xR^6$, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_{1-6}$ alkyl, the latter three groups being optionally substituted by one or more substituents independently selected from halogen atoms, -$OR^6$ and –$NR^4R^5$, where x= 0,1 or 2;

$R^4$ and $R^5$ independently represent a hydrogen atom, a $C_{1-6}$alkyl group, or aryl group the latter two of which may be optionally substituted by one or more substituent groups independently selected from halogen atoms, aryl, -$OR^{12}$ and -$NR^{13}R^{14}$, -$CONR^{13}R^{14}$, -$NR^{13}COR^{14}$,-$SO_2NR^{13}R^{14}$, $NR^{13}SO_2R^{14}$;

~~or~~

~~$R^4$ and $R^5$ together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocylic ring optionally containing one or more atoms selected from O, S, $NR^{15}$, and itself optionally substituted by $C_{1-3}$ alkyl, halogen;~~

$R^6$ represents a $C_{1-6}$alkyl which may be optionally substituted by one or more substituents independently selected from halogen atoms, aryl, -$OR^9$ and –$NR^{10}R^{11}$[[.]]

each of $R^7$, $R^8$ $R^9$, $R^{10}$, $R^{11}$, $R^{12}$, $R^{13}$, $R^{14}$, independently represents a hydrogen atom, $C_1$-$C_6$, alkyl, an aryl or a heteroaryl group which may be optionally substituted by one or more halogen atoms, OH, O-$C_1$-$C_6$alkyl; and

$R^{15}$ is hydrogen, $C_1$-$_4$ alkyl, -$COC_1$-$C_4$ alkyl, -$COQC_1$-$C_4$alkyl, Q=O or $NR^6$**[[,]]**
~~provided that:~~
~~the number of nitrogen atoms within the ring ABDE is 1 or 2 when Y is $CR^2$ and~~
~~$R^3$ cannot be phenyl when Y is C=O and X is nitrogen~~.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Currently amended) A compound according to claim 1 **[[4]]** in which Z is a bond.

6. (Cancelled)

7. (Cancelled)

8. (Previously Presented) A compound according to claim 1 in which Z is sulfur, methylene or a bond.

9. (Currently amended) A compound according to claim 1 selected from:
5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;
5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;
3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and

4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

~~3-[(4-chlorophenyl)thio]-5-iodo-1*H*-indazole-1-acetic acid;~~

~~3-(7-chloro-4-quinolinyl)-2-methyl-1*H*-pyrrolo[2,3-*b*]pyridine-1-acetic acid, sodium salt;~~

~~3-[(4-Chloro-2,4-cyclohexadien-1-yl)thio]-2,5-dimethyl-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~2,5-Dimethyl-3-[[4-(methylsulfonyl)-2,4-cyclohexadien-1-yl]methyl]-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~2,5-Dimethyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~4-Chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~4-Chloro-2-methyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~3-[(4-Chlorophenyl)thio]-2-methyl-4-phenyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~2-Methyl-3-[[4-(methylsulfonyl)phenyl]thio]-4-phenyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

and pharmaceutically acceptable salts thereof.

10. (Cancelled)

11. (Withdrawn) A method of treating a disease mediated by prostaglandin D2, which comprises administering to a patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt as defined in claim 1.

12. (Withdrawn) A method of treating according to claim 11 wherein the disease is asthma or rhinitis.

13. (Cancelled)

14. (Cancelled)

15. (Withdrawn-amended) The method according to claim 11 wherein the compound is selected from:

5-methyl-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

5-cyano-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

3-(6-fluoro-4-quinolinyl)-4-(trifluoromethyl)-1*H*-indazole-1-acetic acid; and

4-iodo-3-(4-quinolinyl)-1*H*-indazole-1-acetic acid;

~~3-[(4-chlorophenyl)thio]-5-iodo-1*H*-indazole-1-acetic acid;~~

~~3-(7-chloro-4-quinolinyl)-2-methyl-1*H*-pyrrolo[2,3-*b*]pyridine-1-acetic acid, sodium salt;~~

~~3-[(4-Chloro-2,4-cyclohexadien-1-yl)thio]-2,5-dimethyl-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~2,5-Dimethyl-3-[[4-(methylsulfonyl)-2,4-cyclohexadien-1-yl]methyl]-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~2,5-Dimethyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-pyrrolo[3,2-*b*]pyridine-1-acetic acid;~~

~~4-Chloro-3-[(4-chlorophenyl)thio]-2-methyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~4-Chloro-2-methyl-3-[[4-(methylsulfonyl)phenyl]thio]-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~3-[(4-Chlorophenyl)thio]-2-methyl-4-phenyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

~~2-Methyl-3-[[4-(methylsulfonyl)phenyl]thio]-4-phenyl-1*H*-pyrrolo[3,2-*c*]pyridine-1-acetic acid;~~

and pharmaceutically acceptable salts thereof.